Global Castrate-Sensitive Prostate Cancer (CSPC) - Market Insights, Epidemiology and Market Forecast to 2030 - ResearchAndMarkets.com

DUBLIN--()--The "Castrate-Sensitive Prostate Cancer (CSPC)- Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the CSPC, historical and forecasted epidemiology as well as the CSPC market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

The CSPC market report provides current treatment practices, emerging drugs, CSPC market share of the individual therapies, current and forecasted CSPC market size from 2017 to 2030 segmented by seven major markets. The Report also covers current CSPC treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Prostate cancer is a type of malignancy that occurs in the prostate gland. It is one of the most common types of cancer found in men. This cancer usually grows slowly and is confined to the prostate gland initially, where it may not cause serious harm. According to the Cancer Treatment Centres of America (CTCA), more than 99% of prostate cancers are adenocarcinomas, which develop in the gland cells. The exact cause of prostate cancer is unknown. However, several things can increase the risk of developing this condition like age, family history, diet, high testosterone level, genome changes, and race.

In the majority of the cases, the symptoms of prostate cancer are not apparent in the early stages of the disease. The symptoms of prostate cancer may be different for each man, and other conditions may cause some of these symptoms like blood in semen, erectile dysfunction, painful ejaculation, pain in pelvic area, and numbness in legs.

Patients who have never received i.e. are sensitive to ADT known as hormone-sensitive prostate cancer (HSPC) or castrate-sensitive prostate cancer (CSPC). And it was accessed that around 78% of biochemical recurrence/ progressive cases are non-metastatic CSPC/ HSPC.

Key Topics Covered:

  1. Key Insights
  2. Executive Summary of CSPC/HSPC
  3. SWOT Analysis of CSPC/HSPC
  4. CSPC/HSPC: Market Overview at a Glance
  5. CSPC/HSPC: Disease Background and Overview
  6. Diagnosis
  7. Epidemiology and Patient Population
  8. EU-5 Country-wise Epidemiology
  9. Japan
  10. Current Treatment Practices: Prostate Cancer
  11. Guideline of Prostate Cancer
  12. Unmet Needs of Prostate Cancer
  13. Marketed Therapies
  14. Emerging Therapies
  15. CSPC/HSPC: Seven Major Market Analysis
  16. 7MM Market Size
  17. Market Access and Reimbursement of CSPC
  18. Market Drivers of CSPC
  19. Market Barriers of CSPC
  20. Appendix
  21. Publisher Capabilities
  22. Disclaimer
  23. About the Publisher

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/l9cj9w

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900